About The Study: The results of this randomized clinical trial showed that a 15-day course of nirmatrelvir-ritonavir in a population of patients with postacute sequelae of SARS-CoV-2 infection (PASC) was generally safe but did not demonstrate a significant benefit for improving select PASC symptoms in a mostly vaccinated cohort with protracted symptom duration. Further studies are needed to determine the role of antivirals in the treatment of PASC.
Corresponding Author: To contact the corresponding authors, email Linda N. Geng, M.D., Ph.D. ( geng@stanford.edu ) and Upinder Singh, M.D. ( usingh@stanford.edu ).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2024.2007)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the Demystifying Long COVID North American Conference 2024.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.2007?guestAccessKey=face4b31-1b6e-498a-a147-cf6a9dee6986&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060724
JAMA Internal Medicine